Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Tacrolimus
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Tacrolimus 0.1% ointment
1305030C0AAAAAA
|
Tacrolimus (Topical) | Tacrolimus | Skin | 49,102 |
|
Tacrolimus 0.03% ointment
1305030C0AAACAC
|
Tacrolimus (Topical) | Tacrolimus | Skin | 16,826 |
|
Protopic 0.1% ointment
1305030C0BBAAAA
|
Protopic | Tacrolimus | Skin | 16,743 |
|
Protopic 0.03% ointment
1305030C0BBABAC
|
Protopic | Tacrolimus | Skin | 8,773 |
|
Prograf 1mg capsules
0802020T0BBABAB
|
Prograf | Tacrolimus | Malignant Disease and Immunosuppression | 7,647 |
|
Adoport 1mg capsules
0802020T0BEAAAB
|
Adoport | Tacrolimus | Malignant Disease and Immunosuppression | 5,878 |
|
Prograf 500microgram capsules
0802020T0BBADAF
|
Prograf | Tacrolimus | Malignant Disease and Immunosuppression | 3,805 |
|
Adoport 0.5mg capsules
0802020T0BEACAF
|
Adoport | Tacrolimus | Malignant Disease and Immunosuppression | 3,375 |
|
Advagraf 1mg modified-release capsules
0802020T0BCABAN
|
Advagraf | Tacrolimus | Malignant Disease and Immunosuppression | 2,514 |
|
Adoport 2mg capsules
0802020T0BEAEBG
|
Adoport | Tacrolimus | Malignant Disease and Immunosuppression | 2,032 |
|
Advagraf 3mg modified-release capsules
0802020T0BCADAT
|
Advagraf | Tacrolimus | Malignant Disease and Immunosuppression | 1,137 |
|
Advagraf 5mg modified-release capsules
0802020T0BCACAP
|
Advagraf | Tacrolimus | Malignant Disease and Immunosuppression | 863 |
|
Adoport 5mg capsules
0802020T0BEABAA
|
Adoport | Tacrolimus | Malignant Disease and Immunosuppression | 690 |
|
Advagraf 0.5mg modified-release capsules
0802020T0BCAAAM
|
Advagraf | Tacrolimus | Malignant Disease and Immunosuppression | 570 |
|
Adoport 0.75mg capsules
0802020T0BEADBF
|
Adoport | Tacrolimus | Malignant Disease and Immunosuppression | 395 |
|
Tacrolimus 1mg capsules
0802020T0AAABAB
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 379 |
|
Prograf 5mg capsules
0802020T0BBAAAA
|
Prograf | Tacrolimus | Malignant Disease and Immunosuppression | 271 |
|
Tacrolimus 500microgram capsules
0802020T0AAAFAF
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 186 |
|
Modigraf 0.2mg granules for oral suspension sachets
0802020T0BDAAAV
|
Modigraf | Tacrolimus | Malignant Disease and Immunosuppression | 149 |
|
Envarsus 1mg modified-release tablets
0802020T0BJAABC
|
Envarsus | Tacrolimus | Malignant Disease and Immunosuppression | 148 |
|
Modigraf 1mg granules for oral suspenion sachets
0802020T0BDABAW
|
Modigraf | Tacrolimus | Malignant Disease and Immunosuppression | 112 |
|
Tacrolimus 5mg/5ml oral suspension
0802020T0AAALAL
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 81 |
|
Envarsus 4mg modified-release tablets
0802020T0BJACBE
|
Envarsus | Tacrolimus | Malignant Disease and Immunosuppression | 73 |
|
Tacrolimus 2mg capsules
0802020T0AABGBG
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 70 |
|
Envarsus 750microgram modified-release tablets
0802020T0BJABBD
|
Envarsus | Tacrolimus | Malignant Disease and Immunosuppression | 56 |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.